SCHEMBL13137259

SCHEMBL13137259

c1ccc2c(c1)CC(NCc1ccc(-c3ccc4cc[nH]c4c3)cc1)C2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.48
GRIN2B Q13224 3/20 0.45
FYN P06241 1/20 0.45
MEN1 O00255 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 1/20 0.44
KDM1A O60341 2/20 0.42
MAOA P21397 2/20 0.42
MAOB P27338 2/20 0.42
BACE1 P56817 1/20 0.40
NPC1 O15118 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
SLC2A1 P11166 2/20 0.39
NR1I3 Q14994 2/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA7 P36544 1/20 0.38
CHRNA10 Q9GZZ6 1/20 0.38
CHRNA9 Q9UGM1 1/20 0.38
PRMT5 O14744 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13137256 0.91 NPC1 (0.52) HDAC1GRIN2BFYNMEN1RAB9A
Acetic Acid SCHEMBL3038340 0.84 HDAC1 (0.52) HDAC1GRIN2BFYNKDM1AMAOA
Acetic Acid SCHEMBL3948445 0.84 HDAC1 (0.52) HDAC1GRIN2BFYNKDM1AMAOA
SCHEMBL13136969 0.79 QPCT (0.47) HDAC1GRIN2BFYNMEN1RAB9A
SCHEMBL13137260 0.78 HRH3 (0.44) MEN1RAB9AKMT2AKDM1AMAOA
SCHEMBL3044397 0.77 HDAC1 (0.46) HDAC1GRIN2BFYNMEN1RAB9A
SCHEMBL3051310 0.77 ROCK2 (0.56) HDAC1GRIN2BFYN
SCHEMBL1787991 0.75 HDAC1 (0.47) HDAC1GRIN2BFYNMEN1RAB9A
SCHEMBL13137070 0.75 HDAC1 (0.42) HDAC1GRIN2BFYNMEN1RAB9A
SCHEMBL1788066 0.74 HDAC1 (0.46) HDAC1GRIN2BFYNMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION 2010-09-02 US disclosed
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION 2010-09-02 US disclosed
WO-2008021851-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS OPRL1, OPRM1, OPRK1 HDAC1 2221/4885GRIN2B 148/4885FYN 2222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.